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Abstract
Background: Hypothermia is neuroprotective in experimental stroke and may extend the so far limited therapeutic
time window for thrombolysis. Therefore, hypothermia of 34°C and its effects on delayed thrombolysis including
reperfusion-associated injury were investigated in a model of thromboembolic stroke (TE).
Methods: Male Wistar rats (n = 48) were subjected to TE. The following treatment groups were investigated:
control group - normothermia (37°C); thrombolysis group - rt-PA 90 min after TE; hypothermia by 34°C applied
1.5 to 5 hours after TE; combination therapy- hypothermia and rt-PA. After 24 hours infarct size, brain edema and
neuroscore were assessed. Protein markers for inflammation and adhesion, gelatinase activity, and blood brain
barrier (BBB) disruption were determined. MRI-measurements investigated infarct evolution and blood flow
parameters.
Results: The infarct volume and brain swelling were smaller in the hypothermia group compared to the other
groups (p < 0.05 to p < 0.01). Thrombolysis resulted in larger infarct and brain swelling than all others.
Hypothermia in combination with thrombolysis reduced these parameters compared to thrombolysis (p < 0.05).
Moreover, the neuroscore improved in the hypothermia group compared to control and thrombolysis. Animals of
the combination therapy performed better than after thrombolysis alone (p < 0.05). Lower serum concentration of
sICAM-1, and TIMP-1 were shown for hypothermia and combination therapy. Gelatinase activity was decreased by
hypothermia in both groups.
Conclusions: Therapeutic hypothermia reduced side-effects of rt-PA associated treatment and reperfusion in our
model of TE.
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Introduction
Thrombolysis by recombinant tissue-plasminogen acti-
vator (rt-PA) is the preferable causal therapy for acute
ischemic stroke, but only a minority of all stroke
patients is eligible for treatment [1]. Its approval is
restricted to the first 4.5 hours after symptom onset
[2,3]. Delayed administration of rt-PA has less pro-
nounced effects on restoration of cerebral blood flow
(CBF) and outcome, but may still be effective [2-4].
However, clinical and animal data suggest an increased
risk for intracerebral hemorrhage and brain edema after
delayed thrombolysis [4,5]. Possibly, these side effects
account to a reperfusion-associated injury [6], pro-apop-
totic and neurotoxic side effects of rt-PA [7,8] with dys-
regulation of Matrix Metalloproteinases (MMPs) and
disruption of the blood brain barrier (BBB) [9].
Hypothermia might be a promising candidate for
combination therapy with rt-PA because of its multiple
neuroprotective effects and capacity to reduce reperfu-
sion associated injury [10,11]. Moreover, it is the only
strategy that succeeded in acute brain injury so far:
moderate hypothermia (33°C) improved functional out-
come and survival of cardiac arrest patients when
applied directly after successful resuscitation [12]. New
approaches to counteract cold-induced shivering
and patient discomfort allow mild hypothermia to be * Correspondence: rainer.kollmar@uk-erlangen.de
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first results from clinical trials suggest that the combina-
tion of rt-PA and hypothermia might be feasible and
safe [14,15].
In this study, we investigated the effects of induced
hypothermia on rt-PA related reperfusion damage in a
model of thromboembolic stroke (TE). Hypothermia of
34°C was used as it was the most effective target tem-
perature in a previous dose escalating study after fila-
ment occlusion of the middle cerebral artery [16].
Infarct size and brain swelling were investigated by sil-
ver infarct staining and magnetic resonance imaging
(MRI). Matrix metalloproteinases-1 (TIMP-1), and
soluble intercellular adhesion molecule (sICAM-1)
were measured as markers of reperfusion- and rt-PA-
associated injury.
Materials and methods
Experimental procedure
Animal experiments were approved by the local ethics
committee. Male Wistar rats (n = 112) weighing 280-
320 g (Charles River, Sulzfeld, Germany) were subjected
to embolic stroke (TE) using a method modified from
Busch [17].
Preliminary study
In a preliminary study (n = 64 animals), the effects of
different red blood clot size and its various preparation
on infarct size, edema and mortality have been tested in
four different groups (n = 16 each). Anaesthesia and
animal preparation were performed as described for the
main body of the study. No rt-PA has been given.
A whole blood sample of 0.5 ml was withdrawn into a
polyethylene catheter (PE-50; NeoLab, Heidelberg, Ger-
many) and allowed to clot for 2 hours. Then, blood
clots were transferred to a 20 mM CaCl2 solution and
incubated over night at 4°C or for several minutes at
room temperature. Prior to cutting clots the calcified
blood was washed in 0.9% NaCl to wash out the CaCl2.
A blood clot of 30 mm or 24 mm length, respectively,
was divided into 12 pieces on a scale paper. Clot pre-
paration according to treatment groups has been done
as follows:
Group 1: Clot incubation time 24 hours, clot size 3
mm, number of clots 12
Group 2: Clot incubation time 2 hours, clot size 3
mm, number of clots 12
Group 3: Clot incubation time 24 hours, clot size 2
mm, number of clots 12
Group 4: Clot incubation time 2 hours, clot size
Group 2 mm, number of clots 12
After 24 hours, the animals have been sacrificed by an
overdose of ketamine (10%) and xylazine hydrochloride
(100 mg/kg body weight). After decapitation, brains
were rapidly removed and dissected into 5 coronal
sections of 2 mm thickness, incubated in a 2% solution
of 2,3,5-triphenyltetrazolium chloride (TTC) at 37°C for
15 minutes until the brains were stained sufficiently and
immersion-fixed in a 4% paraformaldehyde solution.
Slices were scanned into Adobe Photoshop and infarct
size was measured using scion image (Scion corporation,
Maryland, USA) as imaging software. Infarct size is
reported as infarct volume and is corrected for edema.
To compensate for the effect of brain edema, the cor-
rected infarct volume was calculated as previous
described [16]. The following formula was used to cal-
culate the infarct volume corrected for the cerebral
edema [16]: Corrected infarct volume = volume of the
left, nonischemic hemisphere - (volume of the right,
ischemic hemisphere - infarct volume). The volume of
the brain edema has been calculated with the following
formula: the sum of surface areas of the left, non-
ischemic hemisphere divided by the sum of surface
areas of the right, ischemic hemisphere. Infarct size and
size of edema is expressed as % of the contralateral
hemisphere.
Since mortality was the lowest in group 4 of the preli-
minary study and infarct size showed low standard
deviations, clots for animals in the major study were
prepared according to method 4.
Main study
Animals were randomly assigned to one of the following
groups:
Control group (Co): 37°C body core temperature, no
specific treatment (n = 12).
Thrombolysis group (T): 37°C body core temperature,
rt-PA 1.5 h after TE (n = 12).
Hypothermia group (H): 34°C induced 1.5 h after TE
and maintained for 4.5 h (n = 12).
Combination group (TH): 34°C induced 1.5 h after
TE and maintained for 4.5 h plus rt-PA 1.5 h after TE
(n = 12).
General anaesthesia and monitoring of vital signs
Animals were anesthetized using a mixture of halothane
(Halocarbon laboratories), oxygen 30% and N2O( 7 0 % ) .
Minimum alveolar concentrations were corrected for
the actual body temperature. A polyethylene-catheter
(PE-50; Neolab, Heidelberg, Germany) in the right
femoral artery was used for continuous monitoring of
blood pressure, heart frequency, and blood gases during
the experiment as well as blood sampling for measuring
blood protein levels. The right femoral vein was cannu-
lated for administration of rt-PA, placebo or contrast
agent (Magnevist).
Thromboembolic stroke model For induction of TE, the
right common carotid (CCA), internal carotid (ICA),
and external carotid arteries (ECA) were exposed, and
further dissection identified the origin of the pterygopa-
latine artery (PPA). The ECA and the PPA were
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rily clipped for embolization. A PE 50 catheter was
inserted into the ECA proximal to its ligation, and 12
red blood clots (each 0.35 mm in diameter and 2 mm in
length) were injected at the origin of the right middle
cerebral artery (MCA).
Temperature management Rectal temperature was
regulated by a thermostatically controlled heating pad
(Foehr Medical Instruments, Seeheim-Jugenheim, Ger-
many). A rectal probe was inserted 4 cm into the rec-
tum to measure the actual body core temperature. Prior
experimental data indicated that the body core tempera-
ture correlates to intracranial and pericranial tempera-
ture during normothermia and therapeutic hypothermia
[18]. In normothermic rats, a target rectal temperature
of 37°C was achieved by setting the heating pad to 37°C.
For induction of therapeutic hypothermia, the animals
were externally cooled by cooling pads attached to the
abdomen of the animal in the prone position, until a
temperature of 34.5°C was reached. Thereafter, cooling
p a d sw e r er e m o v e df r o ma b d o m e na n dt h eh e a t i n gp a d
was set to 34°C. Within approximately 2-5 min, the ani-
mal reached 34°C which was maintained via the heating
pad for the entire cooling period. The Optimal tempera-
ture of 34°C of body temperature for effective treatment
of experimental stroke has been described in our labora-
tory and cooling of the animals was performed as
described in this previous study [16]. Rewarming was
performed by setting the heating pad to the desired tar-
get temperature of 37°C. The rewarming procedure took
approximately 30 min.
Thrombolytic treatment For thrombolysis, rt-PA
(Boehringer Ingelheim, Germany) 10 mg/kg body weight
was injected 1.5 hours after induction of TE as pre-
viously described [19].
Removal of brain tissue Twenty-four hours after
MCAO, rats were sacrificed by an overdose of ketamine
(10%) and xylazine hydrochloride (100 mg/kg body weight).
After decapitation, brains were rapidly removed, frozen in
i s o p e n t a n ea t- 2 0 ° C ,a n ds t o r e du n t i lu s ea t- 8 0 ° C .
Infarct size and brain edema
The silver infarct staining (SIS) method was used to
evaluate the infarct size. With this method, ischemic
brain tissue can be reliably distinguished from nonis-
chemic white and gray matter of rat brain cryosections
as soon as 2 hours after MCAO [20]. Frozen brains
were dissected into 14-μm sections on 5 coronal levels 2
mm apart from each other. A semiautomated method
was used to measure the cerebral infarct volume and
brain swelling as described previously [19]. The brain
sections were analyzed by an investigator who was
blinded for the treatment of the groups. All reported
data for infarct volume are corrected for edema.
Neuroscore
24 hours after TE, all animals were tested for neurological
outcome using the neuroscore according to Menzies [21]:
0 = no apparent deficit, 1 = contralateral forelimb flexion;
2 = decreased grip of contralateral forelimb grip while tail
pulled; 3 = spontaneous movement in all directions, con-
tralateral circling only if pulled by tail; 4 = spontaneous
contralateral circling. The testing was performed by a co-
worker who was blinded for the earlier treatment regimen.
Immunohistochemistry
Frozen sections of 14 μm thickness out of the level -1.4
to -1.8 mm to bregma were used for immunohistochem-
ical analysis. Studies were performed with antisera
against myeloperoxidase (MPO; DAKO) and performed
according to the manufacturer’s advice.
MPO-positive cells were quantitatively measured
counting MPO positive cells per infarcted and non-
infarcted hemisphere of all groups [16].
In situ Zymography
Frozen cryostat brain sections of ischemic rats (n = 4 per
group) were brought to room temperature (RT) and
incubated with 100 μl FITC-labeled DQ-gelatin (Invitro-
gen, Eugene, USA) overnight at 37°C in a humidified
chamber. These sections had a 14 μmt h i c k n e s so u to f
the level -1.4 to -1.8 mm to bregma. The sections were
washed with PBS, fixed in 1% Paraformaldehyde and
examined by fluorescence microscopy to reveal gelatinase
activity at the cellular level. Sections were also stained
with a monoclonal antibody (mAb) against neuronal
nuclei (NeuN, Chemicon, USA; diluted 1:500) followed
by a Cy3-labeled secondary Antibody (Zymed Labora-
tories, San Francisco, USA). 3 regions of interest (ROI)
were investigated: parietal Cortex, hippocampus, basal
ganglia. A qualitative assessment was performed. A quan-
titative measurement of fluorescence activity according to
gelatinase activity was done and values were expressed as
relative increase of fluorescence in the ischemic hemi-
sphere in contrast to the non-ischemic hemisphere.
Marker-proteins
Arterial blood was drawn at 4 time points to measure
protein values of TIMP-1, and sICAM-1: Prior to TE,
0.5 hours after TE, 4 hours after TE, and 24 hours after
TE. Commercial ELISA Kits were used to determine dif-
ferent protein concentrations (Quantikine rat TIMP-1;
Quantikine rat sICAM-1; all R&D Systems, Wiesbaden,
Germany).
Magnetic resonance imaging (MRI) protocol
Animals were subjected to MRI at three time points:
0.5 hours after TE (DWI, PWI); 4 hours after TE (T2,
PWI); 24 hours after TE (T2, PWI).
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pec 24/40, BRUKER Medizintechnik, Ettlingen, Ger-
many), using an actively shielded gradient coil with an
inner diameter. The coil operates on a standard 150 V/
100 2 gradient power supply. In this configuration, 180
mT/m could be reached in 180 ms. AsRF coil, we used
a home-built birdcage resonator with an inner diameter
of 40 mm. At each time point, MRI data were acquired
for 20 min. MRI sequences are described in detail pre-
viously [19]. No infarcts were observed outside the
imaged regions. A blinded investigator measured the
lesion volumes of the T2- and DWI-weighted MR
images by tracing the area of hyperintense regions. All
reported data for infarct volume are corrected for
edema. From the PWI data, we calculated the relative
regional cerebral blood volume (rrCBV) as described
previously [22] only after TE to assess valid occlusion of
the MCA. PWI data were assessed as region of interest
(ROI) with an area of 3 × 3 pixels at the level of the lat-
eral basal ganglia, which are included in the ischemic
area in the used model. Values were then calculated as a
percentage of the non-ischemic hemisphere.
Statistical analysis
Parametric data such as infarct size and weight were
compared by analysis of variance (ANOVA) and Scheffé
post hoc tests if needed. Physiological data were com-
pared by 2-way ANOVA with 3 within time points.
Fisher’s protected least significant difference (PLSD) cor-
rection confirmed significant group effects. The non-
parametric Kruskall-Wallis test evaluated the neuroscore
with subsequent group comparisons by Mann-Whitney
U test. The Chi square test with Yates correction for
small numbers was used to test for differences in
hemorrhagic transformation and mortality rate. sICAM
and TIMP-1 values were assessed by repeated measures
ANOVA, since blood draws were taken over time.
An alpha error rate of 0.05 was taken as the criterion for
significance for all tests. Data are presented as mean ± SD
if not stated otherwise. Analyses were performed with
StatView
® statistical software (SAS Institute Inc., 1998).
Results
Preliminary study
The mortality rate was the highest in group 2. 10 ani-
mals died before reaching 24 hours. 7 of 16 animals
died in group 1, 9 of 16 animals died in group 2, 6 of
16 animals died in group 3 and only one animal died
in group 4. There was not difference in the infarct size
between group 1, 3 and 4. However, infarct size was
significantly higher in group 2 compared to all other
(p < 0.05). Edema did not differ between the groups
(Figure 1).
Main Study
Physiological parameters
There was no significant difference for the measured
physiological parameters with the exception of the
desired body temperature according to the treatment
group (data not shown). The body temperature was in
the desired range during the experimental period and
during sedation. Levels were 37 ± 0.2°C during nor-
mothermia in all groups and 34 ± 0.2°C during the
hypothermia period. There were no significant differ-
ences within the normo- and hypothermic periods.
Mortality
2 animals of the control group died within 24 hours
after TE. All other groups exhibited 3 dead animals
Figure 1 Infarct size (dark grey bars), and brain swelling (light grey bars) are shown according to clot preparation after 24 hours as a
percentage of the left hemisphere and are presented as mean ± SD. Infarct size is significantly higher compared to all others in group 2 (p
< 0.01; asterisks).
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tistically significant.
Infarct size and brain swelling in silver infarct staining
Infarct volume were calculated as follows: group Co 140
±8 0m m
3, group T 278 ± 102 mm
3,g r o u pH7 5±5 7
mm
3, and group TH 120 ± 42 mm
3. The infarct volume
in group T was significantly larger compared to all
other groups (p < 0.01). Group H showed a significantly
lower infarct size in comparison to group Co and TH
(p < 0.05). Differences in brain swelling accounted to
the same significant differences as shown for infarct
size. Values of infarct volume and brain swelling are
shown as a percentage of the contralateral hemisphere
in Figure 2.
Neuroscore
Group H showed a neuroscore with a median of 2
(range 1 to 4) which was significantly better than group
Co with a score of 3 (range 2 to 4) and T with a median
of 3.5 (range 3 to 4) (p < 0.05). In addition, group TH
had a median score of 2 (range 2 to 4) and therefore
performed better than group T (p < 0.05). There were
no significant differences detectable between the other
groups.
Invasion of MPO positive cells
MPO-positive cells were detectable only in the ischemic
hemisphere. The proportion of invaded leukocytes into
the infarcted hemisphere in group H was 33% of those
counted in the control group and significantly lower
compared to all other (p < 0.05). Data of absolute cells
count per infracted hemisphere are shown in Figure 3.
The number of MPO-positive cells was 55 ± 20 for
group Co, 68 ± 19 for group T, 36 ± 17 for group H,
and 62 ± 21 for group TH.
Serum concentration of sICAM, and TIMP-1
sICAM Levels in the serum increased over time in
group Co and T. In contrast, hypothermia reduced the
increase of sICAM-1 serum levels even when combined
with rt-PA at different time points. sICAM-levels at 4
hours were larger in group T compared to group Co
and H (p < 0.001). After 24 hours, sICAM-levels were
lower for group H and TH compared to all other groups
(p < 0.05). Data is shown in Figure 4.
TIMP-1 Serum-levels showed a similar course as
observed for sICAM-1. A time dependent increase was
pronounced in group T. Hypothermia reduced increase
of TIMP-1 and showed significantly lower levels after 4
and 24 hours compared group T (p < 0.01). Treatment
by hypothermia significantly reduced TIMP-1 levels in
group TH compared to group T at 24 hours (p < 0.05).
Results of TIMP-1 levels are shown in Figure 4.
In situ Gelatinase activity
Gelatinase activity was higher in the ischemic hemi-
sphere compared to the contralateral non-ischemic
hemisphere in all sections. The number of cells showing
gelatinase activity was superior in parietal cortex com-
pared to the other two investigated regions of basal
ganglia and hippocampus (data not shown). Gelatinase
activity was reduced in the cortex by hypothermia and
combination therapy. Immunohistochemical staining
with NeuN indicated predominantly neurons to have
gelatinase activity. Quantitative measurement of fluores-
cence-activity in different ROIs showed a distinct
Figure 2 shows results of the main study. Infarct size and brain swelling in group T are significantly larger than in all other groups (p < 0.01;
asterisks). Infarct size in group Co is larger than in group TH (p < 0.05; paragraph sign). Infarct size and brain swelling are smaller in group H
compared to group Co (p < 0.01) and TH (p < 0.05), double asterisks.
Kallmünzer et al. Experimental & Translational Stroke Medicine 2012, 4:3
http://www.etsmjournal.com/content/4/1/3
Page 5 of 11increase in the ischemic hemisphere compared to the
contralateral side of the brain. However, hypothermic
treatment alone and in combination with rt-PA lead to
smaller activity levels compared to the control group Co
(p < 0.05) and group T (p < 0.01). RT-PA treatment
alone lead to higher activity levels compared to control
(p < 0.05). Hypothermia as mono-therapy showed the
lowest level of gelatinase activity. Exemplary brain slices
are shown in Figure 5 and relative gelatinase activity is
shown in Figure 6.
Magnetic resonance imaging
DWI There were no significant differences detectable
between all treatment groups after 0.5 hours. Exemplary
brain slices of DWI are shown in Figure 6 in compari-
son to T2-WI.
T2-WI Group H showed smaller infarct size after 4
hours compared to all other groups (p < 0.05). There
were no further significant differences comparing all
other groups 4 hours after TE. The size of lesion
volumes measured by T2-WI after 24 hours was similar
to the results observed for histological analysis by the
SIS-method and showed same significant differences.
Exemplary brain slices of T2-WI and DWI are shown in
Figure 7.
PWI Analysis of rrCBV showed a decrease below 25%
which was not different between the treatment groups
after 0.5 hours in all investigated ROIs.
Discussion
This study investigated the effects of hypothermia at a
l e v e lo f3 4 ° Cb o d yc o r et e m p e r a t u r ei nam o d e lo f
thromboembolic stroke and thrombolysis by rt-PA.
Hypothermia lead to the smallest infarct size, reduced
brain swelling, and improved functional neurologic out-
come. This effect was accompanied by reduced serum
markers for the disruption of the BBB. Administration
of rt-PA 90 min after TE resulted in large infarcts and
brain swelling which was associated with high levels of
sICAM, TIMP and gelatinase-activity. These effects
were diminished by induced hypothermia.
Stroke model
In contrast to widely used methods with filament middle
cerebral artery occlusion (MCAO), a model of throm-
boembolic stroke was applied in this study. It may
reflect the effects of rt-PA, including gradual vessel reca-
nalization and microcirculatory consequences more reli-
ably and offers the opportunity to investigate
reperfusion and their effects on the injured brain in a
translational approach. Compared to a previous study,
in which the injection of red blood clots and rt-PA
treatment led to a rather high mortality rate of 40 to
60% [19], this time methodical modifications have
achieved a satisfying survival rate (77%) and allowed
further investigations after 24 hours in an adequate
number of animals. As shown in our preliminary study,
we were able to reach this satisfying model by modifying
clot size and number. MRI data including DWI 30 min
after TE indicated reproducible and similar damage in
all animals and perfusion imaging data showed signifi-
cantly decreased CBF independently from the group.
Therefore, stable vessel occlusion without spontaneous
reperfusion of the clots can be suggested for the first
time period. Since diffusion and T2-weighted imaging
Figure 3 The number of MPO-positive cells in the infarcted hemisphere is shown after 24 hours. The group H showed less positive cells
compared to all others (p < 0.05) as indicated by the asterisks. There were no other significant differences between the groups.
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were induced by this model of stroke.
Effects of thrombolysis on the BBB
Rt-PA treatment after 90 min after TE had two major
effects in the present study compared to the control
group: both, brain edema were larger and indicators for
the disruption of the BBB were increased. S-ICAM-1 is
a relevant marker of adhesion. Experimental [23] and
clinical studies showed its increase after ischemic stroke
[24] and association with increased early mortality [23].
Experimentally, s-ICAM-1 is upregulated after embolic
stroke [23]. The integrity of the basal lamina is in major
parts influenced by non-cellular proteolytic mechanisms.
Matrix metalloproteinases (MMPs) and their endogen-
ous inhibitors, the tissue inhibitors of MMPs (TIMPs)
are both mediators in this system and blood values may
be a surrogate for the integrity of the BBB [25]. Clini-
cally, reperfusion has been associated to reperfusion
i n j u r yi nas u b g r o u po fs t r o k ep a t i e n t s .I nM R I ,t h es o
called HARM (hyperintense acute reperfusion marker)
indicated disruption of BBB and was associated with
hemorrhagic transformation and worse clinical outcome
after adjustment for initial severity [26]. Since the timing
Figure 4 Serum concentrations of sICAM (top) and TIMP-1 (bottom) are presented as mean ± SD. SICAM concentration was larger 4
hours after TE in group T compared to group Co and H (p < 0.001; asterisks). SICAM-concentration was larger in group TH compared to group
Co and group H (p < 0.05). After 24 hours, sICAM concentration was larger in group T compared to group H and TH (p < 0.01) and group Co (p
< 0.05). The concentration in group Co was larger compared to group H and TH (p < 0.01). Levels of significance between the groups were the
same for TIMP-1 concentrations after 4 hours. The TIMP-1 concentration after 24 hours was significantly larger compared to group Co and H (p
< 0.01) and group TH (p < 0.05) as indicated by the asterisks.
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Page 7 of 11Figure 5 Exemplary brain slices of gelatinase-activity measurement in different ROIs are shown. Higher fluorescence intensity could be
observed in group Co and group T. Hypothermia reduces gelatinase activity. Reduction of activity is most prominently in the area of the
hippocampus. BG:Basal ganglia; Kx: Cortex; Hi: Hippocampus CA1-region. Bar: 50 μM.
Figure 6 Relative gelatinase-activity is shown as a percentage of the left, non-ischemic hemisphere and expressed as mean ± SD.
Highest activity could be observed in group T which is significantly higher compared to group Co (p < 0.05) and the groups H and TH (p <
0.01) as indicated by the asterisks. The fluorescence intensity is significantly higher in group Co compared to group H and Th (p < 0.05) as
indicated by the string sign.
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potential acute thrombolytic therapy, early BBB disrup-
tion may be a promising target for adjunctive therapy to
reduce the complications associated with thrombolytic
therapy, broaden the therapeutic window, and improve
clinical outcome.
Effects of hypothermia
The neuroprotective effects of hypothermia are
described in numerous animal experiments of ischemic
stroke and include a multitude of mechanisms [26,27].
Hypothermia reduces for example the cerebral metabo-
lism, the release of neurotoxic aminoacids and oxygen
free radicals, the apoptotical rate, the invasion of leuco-
cytes and the break-down of the blood-brain-barrier
[16,18]. However, the transfer of experimental data on
hypothermia for stroke therapy has not been done suc-
cessfully due to various reasons. First of all, 33°C as the
goal temperature used in earlier clinical studies has not
-even experimentally - been proven to be superior to
any other temperature. A recent study showed a U-
shaped curve of efficacy of hypothermia with an advan-
tage for 34°C compared to 33 or 32°C [16]. We used 34°
C as the goal temperature for the first time in a model
of TE and rt-PA treatment. As seen by the low mortality
rate and best neuroscore, this target temperature was
well tolerated. Moreover, hypothermia reduced the
infarct volume, brain swelling, and invasion of myelo-
peroxidase cells into the ischemic hemisphere compared
to the control group. This is in accordance to data from
the filament occlusion model [16]. The reduction of leu-
kocytes in the ischemic hemisphere contributes to a
reduction in the release of oxygen species, thrombosis,
disruption of the BBB, cerebral edema and plugging of
the microvasculature [11,16,18]. Additionally, hypother-
mia reduced the levels of sICAM-1 and gelatinase activ-
ity levels in the brain after 24 hours compared to the
control group.
The key question of the recent study was whether
hypothermia could influence potentially adverse effects
of rt-PA treatment. Although the neuroprotective capa-
city of hypothermia implicates combination studies with
rt-PA, this topic has been investigated by a very limited
number of animal studies [19,28]. In a previous study,
no additional effects of hypothermia (32°C) could be
shown compared to rt-PA treatment alone [28]. In their
study, thrombolysis by rt-PA 20 mg/kg lead to a favour-
able outcome and therefore beneficial effects of
hypothermia could have been overseen. Moreover,
hypothermia was induced before embolisation which
represents a clinically irrelevant scenario. In another
study, hypothermia of 33°C started 1 hour after TE [19].
Figure 7 Exemplary slides of T2-WI and DWI are shown at different time points. Lesion size is smaller in group H and TH compared to the
normothermic groups. Hyperintense and therefore injured regions discriminate as bright contrast from dark background and are pointed out by
a red line.
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compared to the control group, but not to any other
group after 24 hours. Probably the high mortality rate of
the model made it difficult to observe robust effects of
combination therapy. In the present study, an advanced
TE model with higher survival rates was used. The com-
bination of hypothermia with rt-PA was superior to
thrombolysis alone with respect to levels of sICAM,
TIMP-1 and gelatinase activity.
Limitations
Animal models never display the clinical situation 1:1.
Intravenous rt-PA is approved for the treatment of
acute stroke in a time window from symptom onset of
up to 4,5 hours. However, in this model of TE, detri-
mental effects of rt-PA are recorded already in the 90-
minutes time window. Under different experimental
settings, such as suture occlusion of the middle cere-
bral artery, as seen in the especially instructive studies
of Nowak and co-workers [29,30], related effects may
show different time courses. Another major concern
on the combination of hypothermia with rt-PA
addresses the theory, that lytic activity could be
reduced under lower body temperatures [31] and
reperfusion effects might be reduced, therefore. How-
ever, the thrombolytic efficacy of rt-PA according to
body temperature was not assessed by the present
study protocol. Further work should exclusively con-
centrate on that issue.
Conclusions
The present study shows that mild hypothermia of 34°C
is neuroprotective in a thromboembolic stroke model
when focussing on a 24-hour observation time period.
Moreover, combination with delayed rt-PA treatment
resulted in reduction of infarct volume and parameters
indicating a breakdown of the BBB. Therefore, it can be
suggested that mild hypothermia can reduce side effects
of rt-PA associated treatment. Further investigations
need to evaluate whether hypothermia can extend the
therapeutic time window for thrombolysis.
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